NNVC Stock In The Limelight After This Analyst Sees A 350% Upside Potential – Everything To Know About Its Experimental Drug For Ebola
The biotech firm said it is progressing towards a Phase II clinical trial of its antiviral drug NV-387 for the Bundibugyo Ebola outbreak in the Democratic Republic of Congo.